ARTV
Artiva Stock Plunges 31% After Halting AlloNK Development and Cutting 94% of Staff
The biotech is also exploring strategic alternatives, including a possible merger, sale or liquidation, after two patient deaths and weaker durability data.
Artiva Biotherapeutics ARTV
Artiva Biotherapeutics, Inc. · Nasdaq · Biological Products, (No Diagnostic Substances)
$4.28+0.12%close on Oct. 28, 2026 · volume 2.9M · Yahoo Finance
Price, last 47 sessions
Our coverage
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Oct. 6, 2026 | Fred Aslan Chief Executive Officer, director | Sold 10b5-1 plan | 23,463 | $7.20 | $168,880 |
| Oct. 5, 2026 | Christopher Horan Chief Tech Operations Officer | Sold | 10,340 | $6.84 | $70,697 |
| Oct. 5, 2026 | Jennifer Bush COO, CLO, Compliance Officer | Sold | 8,370 | $6.84 | $57,227 |
| Oct. 5, 2026 | Subhashis Banerjee Chief Medical Officer | Sold | 1,099 | $6.84 | $7,514 |
| Oct. 5, 2026 | Fred Aslan Chief Executive Officer, director | Sold | 61,696 | $6.84 | $421,828 |
| Sept. 8, 2026 | Fred Aslan Chief Executive Officer, director | Sold 10b5-1 plan | 23,429 | $10.92 | $255,746 |
| Sept. 3, 2026 | Christopher Horan Chief Tech Operations Officer | Sold | 10,366 | $11.16 | $115,638 |
| Sept. 3, 2026 | Jennifer Bush COO, CLO, Compliance Officer | Sold | 8,391 | $11.16 | $93,606 |
| Sept. 3, 2026 | Subhashis Banerjee Chief Medical Officer | Sold | 1,100 | $11.16 | $12,271 |
| Sept. 3, 2026 | Fred Aslan Chief Executive Officer, director | Sold | 61,888 | $11.16 | $690,392 |
| Aug. 27, 2026 | Subhashis Banerjee Chief Medical Officer | Sold 10b5-1 plan | 8,222 | $12.01 | $98,736 |
| Aug. 18, 2026 | Subhashis Banerjee Chief Medical Officer | Sold 10b5-1 plan | 429 | $12.00 | $5,148 |
Latest 12 of 15. Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 40 →Results of operations and financial condition · Costs of exit or disposal activities · Financial statements and exhibits
AI summary, unreviewedArtiva Biotherapeutics halts AlloNK development, cuts workforce by 94% and explores strategic alternatives; preliminary cash $319.1 million